...six leukemic ALK-negative ALCL cases and all (100%) had TP53 deletion...Eight of nine (90%) patients with leukemic ALK-negative ALCL died, and their overall survival was significantly shorter than that of the patients with non-leukemic...In the leukemic group, seven of nine (78%) patients were treated with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or modified CHOP.